• 제목/요약/키워드: Sarcopenic

검색결과 44건 처리시간 0.029초

Associations of Sarcopenia and Sarcopenic Obesity With Metabolic Syndrome Considering Both Muscle Mass and Muscle Strength

  • Lee, Jihye;Hong, Yeon-pyo;Shin, Hyun Ju;Lee, Weonyoung
    • Journal of Preventive Medicine and Public Health
    • /
    • 제49권1호
    • /
    • pp.35-44
    • /
    • 2016
  • Objectives: We investigated the associations of sarcopenia-defined both in terms of muscle mass and muscle strength-and sarcopenic obesity with metabolic syndrome. Methods: Secondary data pertaining to 309 subjects (85 men and 224 women) were collected from participants in exercise programs at a health center in a suburban area. Muscle mass was measured using bioelectrical impedance analysis, and muscle strength was measured via handgrip strength. Sarcopenia based on muscle mass alone was defined as a weight-adjusted skeletal muscle mass index more than two standard deviations below the mean of a sex-specific young reference group (class II sarcopenia). Two cut-off values for low handgrip strength were used: the first criteria were <26 kg for men and <18 kg for women, and the second criteria were the lowest quintile of handgrip strength among the study subjects. Sarcopenic obesity was defined as the combination of class II sarcopenia and being in the two highest quintiles of total body fat percentage among the subjects. The associations of sarcopenia and sarcopenic obesity with metabolic syndrome were evaluated using logistic regression models. Results: The age-adjusted risk ratios (RRs) of metabolic syndrome being compared in people with or without sarcopenia defined in terms of muscle mass were 1.25 (95% confidence interval [CI], 1.06 to 1.47, p=0.008) in men and 1.12 (95% CI, 1.06 to 1.19, p<0.001) in women, which were found to be statistically significant relationships. The RRs of metabolic syndrome being compared in people with or without sarcopenic obesity were 1.31 in men (95% CI, 1.10 to 1.56, p=0.003) and 1.17 in women (95% CI, 1.10 to 1.25, p<0.001), which were likewise found to be statistically significant relationships. Conclusions: The associations of sarcopenia defined in terms of muscle mass and sarcopenic obesity with metabolic syndrome were statistically significant in both men and women. Therefore, sarcopenia and sarcopenic obesity must be considered as part of the community-based management of non-communicable diseases.

Prevalence of dynapenic obesity and sarcopenic obesity and their associations with cardiovascular disease risk factors in peritoneal dialysis patients

  • Tabibi, Hadi;As'habi, Atefeh;Najafi, Iraj;Hedayati, Mehdi
    • Kidney Research and Clinical Practice
    • /
    • 제37권4호
    • /
    • pp.404-413
    • /
    • 2018
  • Background: Dynapenic obesity and sarcopenic obesity increase cardiovascular disease (CVD) and mortality in nonuremic patients. The present study was designed to determine the prevalence of dynapenic obesity and sarcopenic obesity and their associations with CVD risk factors in peritoneal dialysis (PD) patients. Methods: All eligible PD patients in Tehran peritoneal dialysis centers were included in this cross-sectional study. Skeletal muscle mass and fat mass were assessed using bioelectrical impedance analysis. Muscle strength and physical performance were determined using hand grip strength and a 4-meter walk gait speed test, respectively. In addition, a 5-mL blood sample was obtained from each patient. Results: The prevalence of dynapenic obesity and sarcopenic obesity were 11.4% and 3.8% in PD patients, respectively. Serum high-sensitive C-reactive protein (hs-CRP), soluble intercellular adhesion molecule type 1, triglyceride, total cholesterol, and low-density lipoprotein cholesterol were significantly higher in PD patients with dynapenic obesity than in dynapenic nonobese and nondynapenic nonobese patients. Similarly, serum concentrations of CVD risk factors in PD patients with sarcopenic obesity were higher than in nonsarcopenic nonobese patients, but these differences were statistically significant only for serum hs-CRP and triglyceride. In addition, muscle strength and skeletal muscle mass percentage were negatively associated with markers of inflammation and dyslipidemia, whereas body fat percentage was positively associated with these CVD risk factors. Conclusion: This study indicates that although the prevalence of dynapenic obesity and sarcopenic obesity are relatively low in PD patients, these disorders may be associated with CVD risk factors.

Gintonin-enriched fraction protects against sarcopenic obesity by promoting energy expenditure and attenuating skeletal muscle atrophy in high-fat diet-fed mice

  • Jin, Heegu;Oh, Hyun-Ji;Nah, Seung-Yeol;Lee, Boo-Yong
    • Journal of Ginseng Research
    • /
    • 제46권3호
    • /
    • pp.454-463
    • /
    • 2022
  • Background: Gintonin-enriched fraction (GEF), a non-saponin fraction of ginseng, is a novel glycolipoprotein rich in hydrophobic amino acids. GEF has recently been shown to regulate lipid metabolism and browning in adipocytes; however, the mechanisms underlying its effects on energy metabolism and whether it affects sarcopenic obesity are unclear. We aimed to evaluate the effects of GEF on skeletal muscle atrophy in high-fat diet (HFD)-induced obese mice. Methods: To examine the effect of GEF on sarcopenic obesity, 4-week-old male ICR mice were used. The mice were divided into four groups: chow diet (CD), HFD, HFD supplemented with 50 mg/kg/day GEF, or 150 mg/kg/day GEF for 6 weeks. We analyzed body mass gain and grip strength, histological staining, western blot analysis, and immunofluorescence to quantify changes in sarcopenic obesity-related factors. Results: GEF inhibited body mass gain while HFD-fed mice gained 22.7 ± 2.0 g, whereas GEF-treated mice gained 14.3 ± 1.2 g for GEF50 and 11.8 ± 1.6 g for GEF150 by downregulating adipogenesis and inducing lipolysis and browning in white adipose tissue (WAT). GEF also enhanced mitochondrial biogenesis threefold in skeletal muscle. Furthermore, GEF-treated skeletal muscle exhibited decreased expression of muscle-specific atrophic genes, and promoted myogenic differentiation and increased muscle mass and strength in a dose-dependent manner (p < 0.05). Conclusion: These findings indicate that GEF may have potential uses in preventing sarcopenic obesity by promoting energy expenditure and attenuating skeletal muscle atrophy.

폐경 여성의 근감소증 및 근감소성비만과 심혈관질환 위험도와의 관련성 연구: 국민건강영양조사(2008-2011) 자료를 활용하여 (Sarcopenia and Sarcopenic Obesity and Their Association with Cardiovascular Disease Risk in Postmenopausal Women : Results for the 2008-2011 Korea National Health and Nutrition Examination Survey)

  • 김미성;손정민
    • 대한지역사회영양학회지
    • /
    • 제21권4호
    • /
    • pp.378-385
    • /
    • 2016
  • Objectives: This study was conducted to investigate the association between sarcopenia and sarcopenic obesity and cardiovascular disease risk in Korean postmenopausal women. Methods: We analyzed data of 2,019 postmenopausal women aged 50-64 years who participated in the Korea National Health and Nutrition Examination Survey in 2008-2011 and were free of cardiovascular disease history. Blood pressure, height, and weight were measured. We analyzed the serum concentrations of glucose, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglyceride levels. Waist circumference was used to measure obesity. Appendicular skeletal muscle mass was measured by dual-energy X-ray absorptiometry. Sarcopenia was defined as the appendicular skeletal muscle mass/body weight<1 standard deviation below the gender-specific means for healthy young adults. The estimated 10-year risk of cardiovascular disease risk was calculated by Pooled Cohort Equation. Subjects were classified as non-sarcopenia, sarcopenia, or sarcopenic obesity based on status of waist circumference and appendicular skeletal muscle mass. Results: The prevalence of sarcopenia and sarcopenic obesity was 16.3% (n=317) and 18.3% (n=369), respectively. The 10-year risk of cardiovascular disease risk in the sarcopenic obesity group was higher ($3.82{\pm}0.22%$) than the normal group ($2.73{\pm}0.09%$) and sarcopenia group ($3.17{\pm}0.22%$) (p < 0.000). The odd ratios (ORs) for the ${\geq}7.5%$ 10-year risk of cardiovascular disease risk were significantly higher in the sarcopenic obesity group (OR 3.609, 95% CI: 2.030-6.417) compared to the sarcopenia group (OR 2.799, 95% CI: 1.463-5.352) (p for trend < 0.000) after adjusting for independent variables (i.e., exercise, period of menopausal, alcohol use disorders identification test (AUDIT) score, income, education level, calorie intake, %fat intake and hormonal replacement therapy). Conclusions: Sarcopenia and sarcopenic obesity appear to be associated with higher risk factors predicting the 10-year risks of cardiovascular disease risk in postmenopausal women. These findings imply that maintaining normal weight and muscle mass may be important for cardiovascular disease risk prevention in postmenopausal women.

Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer

  • Palmela, Carolina;Velho, Sonia;Agostinho, Lisa;Branco, Francisco;Santos, Marta;Santos, Maria Pia Costa;Oliveira, Maria Helena;Strecht, Joao;Maio, Rui;Cravo, Marilia;Baracos, Vickie E.
    • Journal of Gastric Cancer
    • /
    • 제17권1호
    • /
    • pp.74-87
    • /
    • 2017
  • Purpose: Neoadjuvant chemotherapy has been shown to improve survival in locally advanced gastric cancer, but it is associated with significant toxicity. Sarcopenia and sarcopenic obesity have been studied in several types of cancers and have been reported to be associated with higher chemotherapy toxicity and morbi-mortality. The aim of this study was to assess the prevalence of sarcopenia/sarcopenic obesity in patients with gastric cancer, as well as its association with chemotherapy toxicity and long-term outcomes. Materials and Methods: A retrospective analysis was performed using an academic cancer center patient cohort diagnosed with locally advanced gastric cancer between January 2012 and December 2014 and treated with neoadjuvant chemotherapy. We analyzed body composition (skeletal muscle and visceral fat index) in axial computed tomography images. Results: A total of 48 patients met the inclusion criteria. The mean age was $68{\pm}10years$, and 33 patients (69%) were men. Dose-limiting toxicity was observed in 22 patients (46%), and treatment was terminated early owing to toxicity in 17 patients (35%). Median follow-up was 17 months. Sarcopenia and sarcopenic obesity were found at diagnosis in 23% and 10% of patients, respectively. We observed an association between termination of chemotherapy and both sarcopenia (P=0.069) and sarcopenic obesity (P=0.004). On multivariate analysis, the odds of treatment termination were higher in patients with sarcopenia (odds ratio=4.23; P=0.050). Patients with sarcopenic obesity showed lower overall survival (median survival of 6 months [95% confidence interval {CI}=3.9-8.5] vs. 25 months [95% CI=20.2-38.2]; log-rank test P=0.000). Conclusions: Sarcopenia and sarcopenic obesity were associated with early termination of neoadjuvant chemotherapy in patients with gastric cancer; additionally, sarcopenic obesity was associated with poor survival.

Risk Factors for Sarcopenia, Sarcopenic Obesity, and Sarcopenia Without Obesity in Older Adults

  • Kim, Seo-hyun;Yi, Chung-hwi;Lim, Jin-seok
    • 한국전문물리치료학회지
    • /
    • 제28권3호
    • /
    • pp.177-185
    • /
    • 2021
  • Background: Muscle undergoes change continuously with aging. Sarcopenia, in which muscle mass decrease with aging, is associated with various diseases, the risk of falling, and the deterioration of quality of life. Obesity and sarcopenia also have a synergy effect on the disease of the older adults. Objects: This study examined the risk factors for sarcopenia, sarcopenic obesity, and sarcopenia without obesity and developed prediction models. Methods: This machine-learning study used the 2008-2011 Korea National Health and Nutrition Examination Surveys in the analysis. After data curation, 5,563 older participants were selected, of whom 1,169 had sarcopenia, 538 had sarcopenic obesity, and 631 had sarcopenia without obesity; the remaining 4,394 were normal. Decision tree and random forest models were used to identify risk factors. Results: The risk factors for sarcopenia chosen by both methods were body mass index (BMI) and duration of moderate physical activity; those for sarcopenic obesity were sex, BMI, and duration of moderate physical activity; and those for sarcopenia without obesity were BMI and sex. The areas under the receiver operating characteristic curves of all prediction models exceeded 0.75. BMI could predict sarcopenia-related disease. Conclusion: Risk factors for sarcopenia-related diseases should be identified and programs for sarcopenia-related disease prevention should be developed. Data-mining research using population data should be conducted to enhance the effectiveness of early treatment for people with sarcopenia-related diseases through predictive models.

복합운동이 근감소증을 동반한 비만 여성고령자의 신체조성과 기능적 체력 및 근단백질합성 관련 호르몬에 미치는 영향 (The Effect of Combined Exercise on Body Composition, Functional Fitness and Muscle Protein Synthesis Related Hormone in Sarcopenic Obesity Elderly Women)

  • 소용석
    • 한국융합학회논문지
    • /
    • 제7권3호
    • /
    • pp.185-193
    • /
    • 2016
  • 본 연구는 근감소증 비만을 가지고 있는 고령여성의 규칙적인 운동을 통하여 비만 및 근감소증 예방뿐만 아니라 일상생활의 개선 및 대사적 질환들의 예방을 위한 효과적인 프로그램을 제공하는데 목적이 있다. 본 연구대상자는 65세 이상의 여성고령자 중 근감소증 비만군(SG, n=10), 일반 비만군(OG, n=10)을 대상으로 복합운동을 실시하였다. 연구결과 %fat은 SG에서 운동 후 유의하게 감소하는 것으로 나타났다. 사지근육량에서는 SG에서 유의하게 증가한 것으로 나타났다. 기능적 체력의 변화 중 의자에 일어섰다 앉기, 덤벨 들기에서도 SG가 운동 후에 유의하게 증가한 것으로 나타났다. 또한 의자에 앉아 윗몸 앞으로 굽히기에서도 SG와 OG의 비교에서 유의한 차이가 있는 것으로 나타났다. 등 뒤에서 손잡기는 SG가 사후에 유의하게 감소한 것으로 나타났고, 2분간 제자리 걷기는 SG가 사전에 비해 사후에 유의하게 증가한 것으로 나타났다. 성장호르몬은 집단 간에 유의한 차이가 있는 것으로 나타났으며, IGF-1은 SG가 사전에 비해 사후에 유의하게 증가한 것으로 나타났다.

고지방식이 동물모델에서 통곡물 시리얼의 근감소성 비만 예방 효과 (Preventive Effects of Whole Grain Cereals on Sarcopenic Obesity in High-fat Diet-induced Obese Mice)

  • 김미보;이세인;김창희;황재관
    • 산업식품공학
    • /
    • 제22권4호
    • /
    • pp.358-365
    • /
    • 2018
  • 통곡물 시리얼(Whole grain cereal, WGC)이 함유된 식이는 에너지 대사 조절에 중요한 다량영양소(macronutrients)를 제공한다. 본 연구는 고지방식이(high-fat diet, HFD)로 유발된 비만 마우스를 이용하여 WGC의 근감소성 비만 예방 효과에 대해 평가하였다. C57BL/6N 마우스에 정상식이(normal diet, ND), ND+WGC, HFD, HFD+WGC를 12주 동안 제공하였다. WGC는 체중, 식이효율, 체지방 및 지방세포의 크기를 감소시켰다. 또한, WGC는 간 무게 및 간에 축적된 지방을 감소시킴으로써 HFD에 의한 비알코올성 지방간을 개선시켰다. 더욱이, WGC는 비만 마우스 및 정상 마우스의 근육 무게 및 근력을 증가시켰다. 따라서, WGC는 지방 축적을 억제하고 근육량을 증가시키므로 근감소성 비만 예방을 위한 기능성 식품으로 사용될 수 있을 것으로 기대된다.

Effects of Sarcopenic Obesity on Metabolic Syndrome in Korean Elders: Using Data from the Korea National Health and Nutrition Examination Survey (2008-2011)

  • Choi, Hyun-A;Park, Kyung-Min
    • 지역사회간호학회지
    • /
    • 제27권3호
    • /
    • pp.231-241
    • /
    • 2016
  • Purpose: This study was conducted to examine effects of sarcopenic obesity on metabolic syndrome in Korean elders. Methods: This study is based on the analysis of the Korea National Health and Nutrition Examination Survey (KNHANES) with 1,155 subjects (524 men, and 631 women) aged 60 or older, from 2008 to 2011. Sarcopenia was defined as an appendicular skeletal muscle (ASM), divided by weight (%) of <1 SD (standard deviation) below the sex-specific mean for young adults. Obesity was defined as a total body fat percent (men${\geq}$25%, women${\geq}$35%). Results: The prevalence of SO (sarcopenic obesity) was 13.3% among men and 22.5% among women. Both sexes showed a higher total body fat percent, and the SMI (skeletal muscle index) was the lowest in the SO group. Metabolic syndrome was highly prevalent in the SO group (52.5% men, 60.4% women). The SO group showed a higher risk for metabolic syndrome (odds ratio men 6.57 [95% CI 5.19~7.27], women 3.89 [95% CI 2.41~6.29]) than the obese group (men 3.14 [95% CI 1.76~4.14], women 2.54 [95% CI 1.38~4.65]). Conclusion: SO is a major risk factor for metabolic syndrome in Korean elders. Therefore, a nursing program should be given to the Korean elderly SO group to prevent metabolic syndrome.

Exploring Incidence and Potential Risk Factors of Sarcopenic Obesity Among Middle-Aged Women Residing in a Community

  • Jongseok Hwang;Il-Young Moon
    • 대한물리의학회지
    • /
    • 제18권3호
    • /
    • pp.11-19
    • /
    • 2023
  • PURPOSE: This study evaluated the incidence of sarcopenic obesity (SO) and examined the specific risk factors in a community-dwelling middle-aged population of women. METHODS: The present study involved analyzing data from a cross-sectional study that included 1,693 community-dwelling women aged between 40 and 49 years. Various risk factors were investigated, including age, height, weight, body mass index, waist circumference, skeletal muscle mass index, smoking and drinking behaviors, systolic and diastolic blood pressure, fasting glucose levels, as well as triglyceride and cholesterol levels. To ensure the accuracy and validity of the results, a complex sampling technique was employed for data analysis. Each sample weight was calculated through a three-step process by estimating base weight, adjusting it for non-response, and modulating it for post-stratification. RESULTS: The incidence of SO was 4.26% (95% CI: 3.20-5.67%). The clinical risk factors for SO were age, height, weight, body mass index, waist circumference, skeletal muscle mass index, systolic blood pressure, diastolic blood pressure, and levels of fasting glucose, triglycerides, and total cholesterol (p < .05). CONCLUSION: This study explores the prevalence and risk factors of SO among community-dwelling women. It adds to the existing literature on SO and identifies potential risk factors in middle-aged women.